QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=ACA5A047115C601778D96512B821C3CC;jsessionid=B4A70D59FD2FF8F4F3F1C2FFE786C7FC;jsessionid=97BC1CA0AE8630E74AD849959C73884E;jsessionid=8155A85F8F97056967763022702733EF;jsessionid=4C5AF4C985C331C94012EDDF28B2FD59;jsessionid=2D8DADB2D67138F5A8272E666FFD8838 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=ACA5A047115C601778D96512B821C3CC;jsessionid=B4A70D59FD2FF8F4F3F1C2FFE786C7FC;jsessionid=97BC1CA0AE8630E74AD849959C73884E;jsessionid=8155A85F8F97056967763022702733EF;jsessionid=4C5AF4C985C331C94012EDDF28B2FD59;jsessionid=2D8DADB2D67138F5A8272E666FFD8838